Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ALK and ROS1 Overexpression is Very Rare in Colorectal Adenocarcinoma

3 Jul 2014

Abstract excerpt

Crizotinib, a small molecule tyrosine kinase inhibitor, has shown tremendous promise in the treatment of lung adenocarcinomas harboring either ALK or ROS1 rearrangements. Recently, small studies of colorectal carcinomas (CRCs) have suggested an incidence of EML4-ALK translocations of 0.4% to 2.4% and FIG-ROS1 translocations of 0.8%. In lung cancer, screening immunohistochemical staining for ALK and ROS1 has been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Gastric Cancer Management and Outcomes
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24992173
DOI: 10.1097/pai.0000000000000025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ALK and ROS1 Overexpression is Very Rare in Colorectal AdenocarcinomaPMID 24992173Read ↗

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK RearrangementsSemantic proximity Read ↗

<i><scp>ROS</scp>1</i> expression and translocations in non‐small‐cell lung cancer: clinicopathological analysis of 1478 casesSemantic proximity Read ↗

ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.Semantic proximity Read ↗

ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.Semantic proximity Read ↗

Identification of ROS1 rearrangement in gastric adenocarcinomaSemantic proximity Read ↗

Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.Semantic proximity Read ↗

Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.Semantic proximity Read ↗

<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung CancersSemantic proximity Read ↗

Screening for <i><scp>ROS</scp>1</i> gene rearrangements in non‐small‐cell lung cancers using immunohistochemistry with <scp>FISH</scp> confirmation is an effective method to identify this rare targetSemantic proximity Read ↗

ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer.Semantic proximity Read ↗

ROS1-Rearranged Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.